{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-prevention-of-premature-destruction-of-records”
},
“headline”: “SOP for Prevention of Premature Destruction of Records”,
“description”: “This SOP establishes procedures for preventing premature destruction of clinical trial records, ensuring compliance with FDA, EMA, CDSCO, WHO, GDPR, HIPAA, and ICH GCP retention requirements. It includes secure storage, destruction authorization, and CAPA for deviations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Prevention of Premature Destruction of Records

Purpose

The purpose of this SOP is to establish controls that prevent the premature destruction of clinical trial records, ensuring that all documents are retained in accordance with global regulatory requirements. This protects subject rights, preserves data integrity, and maintains inspection readiness.

Scope

This SOP applies to sponsors, investigators, CROs, QA, and archival vendors managing Trial Master Files (TMFs), Investigator Site Files (ISFs), pharmacovigilance records, laboratory data, and all essential documents. It covers paper, electronic, and hybrid records.

Responsibilities

• Sponsor: Defines retention timelines and authorizes destruction after expiry.
• Investigator: Maintains site-level records and ensures no premature destruction.
• Archivist: Secures archives and prevents unauthorized disposal.
• QA: Audits archival systems and verifies compliance with regulatory timelines.
• Vendors: Require sponsor authorization before destruction of stored records.

Accountability

The Sponsor is accountable for defining and approving destruction timelines. QA is accountable for verifying compliance, investigating deviations, and ensuring corrective and preventive actions (CAPA).

Procedure

1. Retention Compliance
1.1 Retain records according to global regulations (FDA, EMA, CDSCO, WHO).
1.2 Retention timelines must be documented in Record Retention Log (Annexure-1).

2. Authorization for Destruction
2.1 No records may be destroyed without formal sponsor authorization.
2.2 Maintain Destruction Authorization Form (Annexure-2).
2.3 Both QA and Sponsor sign off before destruction occurs.

3. Vendor Oversight
3.1 Archival vendors must not destroy records without written approval.
3.2 Maintain Vendor Destruction Oversight Log (Annexure-3).

4. Electronic Records
4.1 eArchives must have system-based retention controls.
4.2 Implement access restrictions to prevent accidental deletion.
4.3 Perform quarterly backup verification.

5. Deviation Management
5.1 Record all premature destruction incidents in Destruction Deviation Log (Annexure-4).
5.2 Conduct root cause analysis and implement CAPA.

6. Training
6.1 Archivists and staff must be trained in retention policies.
6.2 Document training in Training Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• TMF: Trial Master File
• ISF: Investigator Site File
• QA: Quality Assurance
• CRO: Contract Research Organization
• CAPA: Corrective and Preventive Action
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act

Documents

1. Record Retention Log (Annexure-1)
2. Destruction Authorization Form (Annexure-2)
3. Vendor Destruction Oversight Log (Annexure-3)
4. Destruction Deviation Log (Annexure-4)
5. Training Log (Annexure-5)

References

• ICH E6(R2/R3) – Essential Document Retention
• FDA – Record Retention and Destruction Guidance
• EMA – Record Preservation Standards
• CDSCO – Record Retention Rules
• WHO – Clinical Trial Record Management

Version: 1.0

Approval Section

Annexures

Annexure-1: Record Retention Log

Annexure-2: Destruction Authorization Form

Annexure-3: Vendor Destruction Oversight Log

Annexure-4: Destruction Deviation Log

Annexure-5: Training Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-record-retention-global-durations-and-triggers”
},
“headline”: “SOP for Record Retention (Global Durations and Triggers)”,
“description”: “This SOP outlines procedures for record retention in clinical trials, including global retention durations and triggers, in compliance with FDA, EMA, CDSCO, WHO, GDPR, HIPAA, and ICH GCP requirements. It covers paper and electronic documents, ISF/TMF, pharmacovigilance records, and inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Record Retention (Global Durations and Triggers)

Purpose

The purpose of this SOP is to establish standardized procedures for record retention in clinical trials, defining global durations and triggers that align with ICH GCP, FDA, EMA, CDSCO, WHO, GDPR, and HIPAA requirements. Proper record retention ensures availability of essential documents for audits, inspections, pharmacovigilance, and legal defense.

Scope

This SOP applies to sponsors, investigators, CROs, QA, and vendors involved in maintaining clinical trial documentation. It covers retention and archiving of Trial Master File (TMF), Investigator Site File (ISF), laboratory data, pharmacovigilance records, informed consent forms, electronic data, and subject safety information.

Responsibilities

• Sponsor: Defines record retention policy and ensures global compliance.
• Investigator: Maintains ISF and site-level essential records.
• QA: Audits record retention practices and verifies compliance.
• Data Management: Maintains electronic records and databases.
• Vendors: Archive and retain outsourced records securely.

Accountability

The Sponsor is accountable for defining retention timelines and ensuring implementation across regions. QA is accountable for oversight of retention records and inspection readiness.

Procedure

1. Retention Durations by Region
1.1 FDA (US): Retain essential records for at least 2 years after the last marketing approval or trial discontinuation.
1.2 EMA (EU): Retain essential documents for 25 years or longer if required by protocol.
1.3 CDSCO (India): Retain trial records for minimum 5 years after completion.
1.4 WHO: Recommend retention of critical records for 15 years.
1.5 GDPR/HIPAA: Retention must also respect privacy laws and subject rights.

2. Retention Triggers
2.1 Records must be retained until the last marketing approval or withdrawal of product.
2.2 Pharmacovigilance records must be retained as per DSUR/PSUR requirements.
2.3 Retain subject safety and informed consent forms per protocol and regional laws.

3. Types of Records
3.1 TMF and ISF essential documents.
3.2 Source documents and CRFs.
3.3 Safety and pharmacovigilance reports (SAE, SUSAR, DSUR, PSUR).
3.4 Laboratory raw data, calibration logs, and validation reports.
3.5 Training, monitoring, and audit reports.

4. Storage Requirements
4.1 Store paper records in secure, access-controlled facilities.
4.2 Archive electronic records in validated eSystems with audit trails.
4.3 Perform periodic data integrity checks.

5. Destruction
5.1 Destruction is permitted only after retention timelines expire and with sponsor approval.
5.2 Maintain Certificate of Destruction (Annexure-1).

6. Inspection Readiness
6.1 All retained records must be easily retrievable for regulatory inspections.
6.2 Maintain Record Retention Log (Annexure-2).

Abbreviations

• SOP: Standard Operating Procedure
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization
• WHO: World Health Organization
• DSUR: Development Safety Update Report
• PSUR: Periodic Safety Update Report
• CRF: Case Report Form
• QA: Quality Assurance

Documents

1. Certificate of Destruction (Annexure-1)
2. Record Retention Log (Annexure-2)

References

• ICH E6(R2/R3) – Clinical Trial Essential Documents
• FDA – Record Retention Guidance
• EMA – Trial Document Retention Rules
• CDSCO – Record Retention Requirements
• WHO – Record Management in Clinical Trials
• GDPR – Data Retention and Privacy

Version: 1.0

Approval Section

Annexures

Annexure-1: Certificate of Destruction

Annexure-2: Record Retention Log

Revision History

For more SOPs visit: Pharma SOP